Auron Therapeutics is developing next-generation targeted cancer therapies by identifying and targeting the drivers of the disrupted cell states found in cancer, and reverting cancer cells from a plastic, proliferative cell state to a more mature, non-proliferative cell state. Using its AURIGIN™ platform, Auron is building a pipeline of small molecule targeted therapies, led by AUTX-703, for the treatment of both solid tumors and hematologic malignancies.
Auron Therapeutics Announces AUTX-703 Granted Fast Track Designation by the FDA for Relapsed or Refractory Acute Myelogenous Leukemia
Newton, MA, February 24, 2025 – Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AUTX-703 for the treatment of patients with relapsed or refractory (r/r) acute myelogenous leukemia (AML).